IMMUNEERING CORP - CLASS A (IMRX) Stock News
NASDAQ:IMRX - Nasdaq - US45254E1073 - Common Stock - Currency: USD
IMRX Latest News, Press Relases and Analysis
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)...
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference...
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Why Is Immuneering Stock Trading Higher On Tuesday?
Immuneering reveals promising Phase 2a pancreatic cancer trial updates for IMM-1-104, showcasing efficacy, safety, and future expansion plans.
Immuneering Launches Pancreatic Cancer Advisory Board
Immuneering Launches Pancreatic Cancer Advisory Board ...
Why is Immuneering (IMRX) Stock Up 24% Today?
Up nearly 25% in today's session on a fast track designation for a key pancreatic cancer drug candidate, IMRX stock is coming into focus.
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
Why Is Immuneering Stock Trading Higher On Tuesday?
On Tuesday, Immuneering Corporation (NASDAQ:IMRX) revealed data updates from three pancreatic cancer arms of its ongoing Phase 2a trial of lead program IMM-1-104 and plans to expand the Phase 2a trial to include three additional combination arms. Updated data from the Phase 2a arm of IMM-1-104 with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer shows: As of December 5, 2024, three patients achieved complete or partial responses for an overall response rate of 43% (3/7) and a
Neue Möglichkeiten der Krebsbehandlung durch hochmoderne Immuntherapien
/PRNewswire/ -- USA News Group Nachrichtenkommentar – Die jüngsten Fortschritte in der Krebsbehandlung demonstrieren weiterhin das transformative Potenzial...
Les immunothérapies de pointe redéfinissent les options de traitement du cancer
/PRNewswire/ -- USA News Group News Commentary - Les récentes avancées dans le traitement du cancer continuent de souligner le potentiel transformateur des...
How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options
/PRNewswire/ -- USA News Group News Commentary – Recent advancements in cancer treatment continue to underscore the transformative potential of innovative...
Immuneering Launches Pancreatic Cancer Advisory Board
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025...
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma ...
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
Immuneering to Present at the Piper Sandler 36th Annual Healthcare Conference...
Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates...
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in...
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates...
